Open Access

Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients

  • Authors:
    • Bing Bai
    • Yanyan Lin
    • Jinjing Hu
    • Haiping Wang
    • Lu Li
    • Sheng Zhao
    • Jinduo Zhang
    • Wenbo Meng
    • Ping Yue
    • Zhongtian Bai
    • Xun  Li
  • View Affiliations

  • Published online on: January 22, 2019     https://doi.org/10.3892/or.2019.6977
  • Pages: 1539-1548
  • Copyright: © Bai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

It has been revealed by our previous proteomic study that the expression profile is different between well‑differentiated and poorly differentiated hepatocellular carcinoma (HCC). Among those differently expressed proteins, peroxiredoxin2 (PRDX2) was our protein of interest. The present study aimed to further investigate the value of PRDX2 as a prognostic factor in HCC. Tissue microarrays were used to investigate the expression difference between HCC tissues and their adjacent normal liver tissues. The expression of PRDX2 at both mRNA and protein levels was examined by q‑RT‑PCR, western blotting and immunohistochemical assessment in HCC tissues and cell line HCCLM3. Silencing of PRDX2 in HCCLM3 was achieved usingpGMLV‑SC1 lentiviral vectors. Cell Counting Kit‑8 (CCK‑8) and Transwell migration assays were used to assess cell proliferation and migration, respectively. Categorical variables were assessed using the Chi‑square test, and ordinal variables were examined using the Mann‑Whitney U test. The difference of continuous variables between groups were compared with t‑tests. The Kaplan‑Meier method was used to calculate the overall survival (OS) and disease‑free survival (DFS) of patients, and the log‑rank test was used to analyze the differences between groups. The results revealed that the expression of PRDX2 was decreased at both the mRNA and protein levels in an HCC cell line compared to that of a normal human liver cell line. PRDX2 protein expression levels were significantly downregulated in HCC tissues and were positively linked to overall survival (OS) and disease‑free survival (DFS) of HCC patients. Patients with high PRDX2 expression levels had longer OS and DFS times than those with lower PRDX2 expression. Silencing of PRDX2 in the HCC cell line HCCLM3 promoted cancer cell proliferation and migration. Our findings indicated that PRDX2 may play an important role in HCC development; PRDX2 may serve as a useful prognostic factor and a therapeutic target.
View Figures
View References

Related Articles

Journal Cover

March-2019
Volume 41 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bai B, Lin Y, Hu J, Wang H, Li L, Zhao S, Zhang J, Meng W, Yue P, Bai Z, Bai Z, et al: Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients. Oncol Rep 41: 1539-1548, 2019
APA
Bai, B., Lin, Y., Hu, J., Wang, H., Li, L., Zhao, S. ... Li, X. (2019). Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients. Oncology Reports, 41, 1539-1548. https://doi.org/10.3892/or.2019.6977
MLA
Bai, B., Lin, Y., Hu, J., Wang, H., Li, L., Zhao, S., Zhang, J., Meng, W., Yue, P., Bai, Z., Li, X."Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients". Oncology Reports 41.3 (2019): 1539-1548.
Chicago
Bai, B., Lin, Y., Hu, J., Wang, H., Li, L., Zhao, S., Zhang, J., Meng, W., Yue, P., Bai, Z., Li, X."Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients". Oncology Reports 41, no. 3 (2019): 1539-1548. https://doi.org/10.3892/or.2019.6977